Sanofi aventis and Merck to Create a Global Leader in Animal Health | Business Wire
 March 09, 2010 02:00 AM Eastern Daylight Time Sanofi aventis and Merck to Create a Global Leader in Animal Health
&#8211; Sanofi aventis exercises its option to combine Merial with Intervet/Schering Plough in a new equally owned Joint Venture with Merck &#8211;
PARIS & WHITEHOUSE STATION, N.J.  Merck & Co., Inc. NYSE: MRK : &#8220;The upcoming combination of Merial and Intervet/Schering Plough is an exciting opportunity for sanofi aventis to create with Merck a leading company in the Animal Health strategic and growing sector&#8221;
 &#160;  &#160;  &#160;  &#160; CONFERENCE CALL & WEBCAST
 &#160; Sanofi aventis and Merck will host a conference call today, at 2:00 p.m. Paris Time CET 8:00 a.m. NY Time EST  &#160;  &#160; See details for the conference call at the end of the release.&#160;  &#160;  Sanofi aventis EURONEXT: SAN NYSE: SNY and Merck & Co., Inc. NYSE: MRK announced today that sanofi aventis has exercised its option to combine Merial with Intervet/Schering Plough, Merck&#8217;s Animal Health business, to create a global leader in Animal Health.The new joint venture will be equally owned by Merck and sanofi aventis.The formation of this new animal health joint venture is subject to execution of final agreements, antitrust review in the United States, Europe and other countries and other customary closing conditions.The completion of the transaction is expected to occur in approximately the next 12 months.&#8220;The upcoming combination of Merial and Intervet/Schering Plough is an exciting opportunity for sanofi aventis to create with Merck a leading company in the Animal Health strategic and growing sector,&#8221; said Christopher A. Viehbacher, Chief Executive Officer of sanofi aventis.&#8220;I am convinced that, together, we will create strong value in bringing broader and improved offerings in both pet and production animal segments.This transaction represents another consistent milestone in our diversification strategy to bring sustainable growth to sanofi aventis.&#8221;  "Merck has been in the animal health business for well over six decades and through this new joint venture, we will<b><font color='green'> bolster our diverse portfolio</font></b> and create a new global competitor poised for growth," said Richard T. Clark, Merck Chairman, President and Chief Executive Officer."This new joint venture delivers on Merck's commitment to customer focus by creating one of the broadest portfolios of animal health products and services in pharmaceuticals and biologics for millions of customers who include farmers, veterinarians and pet owners.The planned joint venture will have an attractive geographical network of global technology and expertise to provide health solutions based on customers' needs, which often vary regionally."  The entreprise value of Merial has been fixed at $8 billion and the entreprise value of Intervet/Schering Plough at $8.5 billion, leading to a true up payment of $250 million to Merck to establish a 50/50 joint venture.An additional amount of $750 million will be paid by sanofi aventis, as per the terms of the agreement signed on July 29, 2009.All payments, including adjustments for debt and certain other liabilities will be made upon closing of the transaction.This new joint venture will offer a broader portfolio of animal health products and services in pharmaceuticals and biologics, as well as the ability to capitalize on growth opportunities in all fields and countries around the world.The worldwide animal health market reached $19 billion in 2008.Products for companion animals accounted for 40 percent of total sales while products for production animals accounted for the remaining 60 percent of total sales.This market is expected to grow at around 5 percent per year over the next 5 years, driven by a growing demand for animal proteins, as well as a strong consumer needs for companion animal health care.The&#160;companies said&#160;that both Merial and Intervet/Schering Plough will continue to operate independently until the closing of the transaction.Today's Merck is working to help the world be well.Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.We also demonstrate our commitment to increasing access to health care through far reaching programs that donate and deliver our products to the people who need them.Merck.Be Well.For more information, visit About sanofi aventis
 Sanofi aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone.Sanofi aventis is listed in Paris EURONEXT: SAN and in New York NYSE: SNY .About Intervet/Schering Plough
Intervet/Schering Plough Animal Health
, based in Boxmeer, the Netherlands, is focused on the research, development, manufacturing and marketing of animal health products.The company offers customers one of the broadest, most innovative animal health portfolios, spanning products to support performance and to prevent, treat and control disease in all major farm and companion animal species.Intervet/Schering Plough Animal Health
 is a fully owned business unit of Merck & Co., Inc., based in Whitehouse Station NJ, USA.For more information about Intervet/Schering Plough Animal Health
 Merial is a world leading, innovation driven animal health company, providing a comprehensive range of products to enhance the health, well being and performance of a wide range of animals.Merial employs approximately 5,700 people and operates in more than 150 countries worldwide.Formed in 1997, Merial is a leading animal health company that was a 50/50 joint venture between Merck and sanofi aventis and is now a wholly owned subsidiary of sanofi aventis, after Sanofi aventis<b><font color='lime'> acquired Merck&</font></b>#8217;s interest in Merial for a cash consideration of $4 billion US in 2009.For more information, please see&#160;
Forward Looking Statements by Merck
 This news release includes &#8220;forward looking statements&#8221; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.Such statements may include, but are not limited to, statements about the<b><font color='green'> benefits</font></b> of the<b><font color='lime'> merger</font></b> between Merck and Schering Plough, including future financial and operating results, the combined company&#8217;s plans, objectives, expectations and intentions and other statements that are not historical facts.Such statements are based upon the current beliefs and expectations of Merck&#8217;s management and<b><font color='red'> are subject</font></b> to significant risks and uncertainties.Actual results may differ from those set forth in the forward looking statements.The following factors, among others, could cause actual results to differ from those set forth in the forward looking statements: the possibility that the<b><font color='lime'> expected synergies from the merger of Merck</font></b> and Schering Plough will not be realized, or will not be realized within the expected time period, due to, among other things, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck&#8217;s ability to accurately predict future market conditions;<b><font color='green'> dependence</font></b> on the<b><font color='green'> effectiveness</font></b> of Merck&#8217;s patents and other protections for<b><font color='green'> innovative products</font></b>; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.Merck undertakes no obligation to publicly update any forward looking statement, whether as a result of new information, future events or otherwise.Additional factors that could cause results to differ materially from those described in the forward looking statements can be found in Merck&#8217;s 2009 Annual Report on Form 10 K and the company&#8217;s other filings with the Securities and Exchange Commission SEC available at the SEC&#8217;s Internet site Forward Looking Statements by sanofi aventis
 This press release contains forward looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended.Forward looking statements are statements that are not historical facts.These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential and statements regarding future performance.Forward looking statements are generally identified by the words &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;plans&#8221; and similar expressions.Although sanofi aventis&#8217; management believes that the expectations reflected in such forward looking statements are reasonable, investors are cautioned that forward looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward looking information and statements.These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group&#8217;s ability to benefit from external growth opportunities as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi aventis, including those listed under &#8220;Risk Factors&#8221; and &#8220;Cautionary Statement Regarding Forward Looking Statements&#8221; in sanofi aventis&#8217; annual report on Form 20 F for the year ended December 31, 2008.Other than as required by applicable law, sanofi aventis does not undertake any obligation to update or revise any forward looking information or statements.&#160;  &#160;  &#160;  &#160; TUESDAY MARCH 9, 2010 CONFERENCE CALL & WEBCAST
 &#160; Sanofi aventis and Merck will host a conference call today, Tuesday March 9, 2010
at 2:00 p.m. CET 8:00 a.m. EST  &#160;  &#160;  France: +33 0 1 72 00 15 29  UK: +44 0 203 367 94 59  USA: +1 866 907 59 28  &#160;  &#160;  France: +33 0 1 72 00 15 00  UK: +44 0 203 367 94 60  USA: +1 877 642 30 18  Access code: 269754#  Replay available until March 19, 2010  &#160;  The presentation and a webcast of the conference call will be available on the websites
www.sanofi aventis.com
 &#160;  &#160;  The presentation will be followed by a Q&A session.&#160;  &#160;  Photos/Multimedia&#160;Gallery Available: http://www.businesswire.com/cgi bin/mmg.cgi?eid=6206910&lang=en
 Contacts Jean Marc Podvin, +33 1 53 77 44 50
S&#233;bastien Martel, +33 1 53 77 45 45
David Caouette, 908 423 34 61
Carol Ferguson, 908 423 44 65  http://www.businesswire.com/news/home/20100308006954/en/Sanofi aventis Merck Create Global<b><font color='green'> Leader Animal Health Smart</font></b> Multimedia Gallery  Download Formats  More  Download Formats  More Company Information Center
More Business Wire sites
